Skip to content
Review Open access

Passive Digital Marker-enabled identification and engagement for Alzheimer’s disease and related dementias care in primary care: the INCLUDE study protocol

Sep 2026 · BMJ Open · Vol 16, pp. e116755 · 0 citations · 58 references
Medicine

TL;DR

A feasibility study to develop and evaluate a patient-informed secure messaging intervention paired with PDM-based risk stratification to enhance patient engagement in cognitive assessment in primary care settings is outlined.

Abstract

Abstract Introduction More than half of older adults living with Alzheimer’s disease and related dementias (ADRD) never receive a formal diagnosis, and when a diagnosis occurs, it is often years after symptom onset. Primary care clinicians are ideally positioned to detect ADRD early; however, current workflows lack scalable tools that support systematic identification and follow-up. The Passive Digital Marker (PDM), a machine learning model that uses structured electronic health record (EHR) data, can identify patients at elevated risk for ADRD without adding burden to clinicians. This protocol outlines a feasibility study to develop and evaluate a patient-informed secure messaging intervention paired with PDM-based risk stratification to enhance patient engagement in cognitive assessment in primary care settings. Methods and analysis This will be a non-randomised pilot study conducted across 12 single health system primary care clinics. The PDM will be applied to EHR data to identify patients aged ≥65 years who are at high risk for ADRD. High-risk patients will receive a co-designed secure message prior to and after upcoming primary care visits encouraging follow-up evaluation with a trained nurse, the Brain Health Navigator (BHN). The primary objectives are to: (1) determine the feasibility of applying the PDM to EHR data across 12 primary care clinics; (2) assess the feasibility of engaging patients identified as positive on the PDM through secure text messaging prior to a primary care encounter and (3) evaluate engagement with the BHN following secure text messaging. Study outcomes will assess the feasibility of implementing the PDM and secure messaging workflow, including identification of high-risk patients using the PDM, message delivery and patient engagement measured through message open rates, completion of cognitive concern questions and appointments scheduled with the BHN. Quantitative data will be analysed using descriptive statistics. Ethics and dissemination This study was deemed exempt as part of enhanced patient care. The findings will be disseminated through peer-reviewed publications, professional conferences, health system reports and public-facing communications. Trial registration number NCT07016178.

Read PDF

Similar papers

Review Open access Sep 2026

A stakeholder-engaged process to design and implement the Assessment of Cognitive Complaints Toolkit for Alzheimer’s Disease (ACCT-AD) in primary care

Dementia is underdiagnosed, particularly in primary care settings where most people receive their healthcare. These is a need for tools to assist with the diagnosis of dementia by primary care clinicians, who greatly outnumber specialists. To describe the collaborative design process, developmental and fea...

A. Sideman, Cecilia Alagappan, Ignacia Arteaga et al. · 0 citations
Open access Sep 2026

Enhancing Alzheimer’s disease diagnosis in primary care through targeted screening of people at risk of developing dementia – study design and feasibility assessment of the PREDEM primary care study

This pilot study demonstrates the feasibility of the PREDEM primary care study design and data collection procedures and targeted recruitment of older adults with cardiometabolic risk factors was able to identify a population relevant to the study aims.

Sandar Aye, Signe Åhrberg, Axel C. Carlsson et al. · 0 citations
Open access Jul 2026

Remote digital cognitive assessment in a trial‐ready Alzheimer's disease cohort: A scalable approach for early intervention studies

High‐frequency remote cognitive assessment is feasible, reliable, and valid in a relatively young international ADAD cohort, supporting its integration into early‐intervention studies.

A. Aschenbrenner, Hannah M. Wilks, Matthew S. Welhaf et al. · 1 citation
Review Open access

Shedding light on the future of dementia diagnosis

As the global burden of dementia continues to rise, there is a growing need for accessible, scalable, and precise approaches to cognitive and functional assessment in dementia diagnosis and care. Digital cognitive and functional assessments hold promise in this regard, particularly as disease-modifying treatments incre...

Sophia Maureen van der Landen · 0 citations
Review Open access Sep 2026

Diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: Findings from an Italian real-world survey.

The real-world diagnostic journey, barriers, and management pathways of MCI and mild AD dementia patients in Italy is characterized to characterize the real-world diagnostic journey, barriers, and management pathways of biomarker-based diagnostics in Italy.

S. Ippati, Federico Torelli, Giovanna Zamboni et al. · 0 citations
Review Open access Aug 2026

Blood-Based Biomarkers for Alzheimer Disease in Primary Care

Blood-based biomarkers (BBMs) for Alzheimer disease (AD) have accelerated the prospect of earlier and more accessible detection of AD pathology, potentially beyond specialist settings. However, their introduction in primary care raises important questions about clinical sequencing, interpretability, pathway consequence...

Jemma Hazan, S. Salemme, Kathy Y. Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.